As of Friday close, Karyopharm Therapeutics Inc.’s (NASDAQ:KPTI) stock was up $0.2, moving up 3.89 percent to $5.34. The average number of shares traded per day over the past five days has been 3,345,100 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.74 fall in that time frame. In the last twenty days, the average volume was 2,532,615, while in the previous 50 days, it was 2,720,878.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, KPTI stock retreated -33.66%. Shares of the company fell to $4.97 on 05/12/22, the lowest level in the past month. A 52-week high of $14.73 was reached on 02/18/22 after having rallying from a 52-week low of $4.42. Since the beginning of this year, KPTI’s stock price has dropped by -16.95% or -$1.09, and marked a new high 17 times. However, the stock has declined by -63.75% since its 52-week high.
Karyopharm Therapeutics Inc. (KPTI) last reported insider trading activity 75 days ago on Feb 28. Frenkel Ran, the EVP, Chief Dev. Officer of the company, disposed of 1,663 shares for $10.24 on Feb 28. It resulted in a $17,025 divestment by the insider. Mason Michael sold 2,398 shares at an average price of $10.24 on Feb 28. The insider now owns 139,110 shares following the transaction. On Feb 28, Chief Scientific Officer Shacham Sharon sold 6,226 shares at $10.24 apiece. The transaction was valued at $63,739.
In the three months ended March 30, Karyopharm Therapeutics Inc.’s quick ratio stood at 4.10, while its current ratio was 4.20, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 98.30% percent. In the year ended March 30, operating margins totaled -34.30%. Based on annual data, KPTI earned $206.42 million in gross profit and brought in $209.82 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -44.30%. Return on equity (ROE) for the past 12 months was 116.30%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. KPTI’s revenue rose 51.21% to $126.27 million during the quarter, while net income inched up to $47.67 million. While analysts expected Karyopharm Therapeutics Inc. to report -$0.63 quarterly earnings, the actual figure was -$0.53 per share, beating the consensus estimate by 15.90%. During the quarter, the company generated -$34.17 million in EBITDA. The liabilities of Karyopharm Therapeutics Inc. were 377.11 million at the end of its most recent quarter ended March 30, and its total debt was $313.58 million. The value of shareholders’ equity is $79.42 million.
This quick technical analysis looks at Karyopharm Therapeutics Inc.’s (KPTI) price momentum. With a historical volatility rate of 144.90%, the RSI 9-day stood at 36.36% on 13 May.
With respect to its five-day moving average, the current Karyopharm Therapeutics Inc. price is down by -12.17% percent or -$0.74. At present, KPTI shares trade -31.54% below its 20-day simple moving average and -16.04% percent below its 100-day simple moving average. However, the stock is currently trading approximately -14.70% below its SMA50 and -36.20% below its SMA200.
Stochastic coefficient K was 12.64% and Stochastic coefficient D was 15.98%, while ATR was 0.59. Given the Stochastic reading of 18.41% for the 14-day period, the RSI (14) reading has been calculated as 37.31%. As of today, the MACD Oscillator reading stands at -0.60, while the 14-day reading stands at -0.78.
JP Morgan upgraded its rating on Karyopharm Therapeutics Inc. (NASDAQ: KPTI) to a Neutral in a note to investors on February 09, 2022. The analysts firm previously had an Underweight rating on the stock.Karyopharm Therapeutics Inc. (KPTI) has been rated Overweight by analysts. According to 0 brokerage firms, KPTI is a sell, and 5 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 2 analysts rate Karyopharm Therapeutics Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $10.00, the current consensus forecast for the stock is $5.00 – $21.00. Based on these forecasts, analysts predict Karyopharm Therapeutics Inc. (KPTI) will achieve an average price target of $11.89.